Conservative therapy of chronic heart failure: glyflosins destroy the worldview
Keywords:cardiac insufficiency, gliflozins, dapagliflozin, cardioprotective mechanism, new indication for administration
Medications representing a new class of drugs – inhibitors of sodium-glucose transport protein type 2 (SGLT2 inhibitors, gliflozins) have appeared in the clinical practice relatively recently. Now they are a new hope for the treatment of chronic heart failure (HF) in patients with/without type 2 diabetes mellitus (DM2). The article briefly discusses the main mechanisms of action of gliflozins, which allowed their active use in clinical practice, in particular, the ability of gliflosins to affect the size and the functional activity of epicardial adipose tissue, as well as the state of the sympathetic nervous system, thereby preventing the development of HF. The main results of the large-scale randomized clinical trials, such as CANVAS, CREDENCE, EMPA, EMPAREG OUTCOME, DECLARE-TIMI 58 are presented. They analyze the effects of canagliflozin, empagliflozin, dapagliflozin on various cardiovascular outcomes: cardiovascular death, myocardial infarction, nonfatal stroke, HF, frequency of hospitalizations caused by HF. Modern concepts of the probable mechanisms of the cardioprotective action of gliflozins are given. The results of meta-analyses revealing the possibility of including gliflozins in the treatment of HF, DM2, as well as those who studied the cardiovascular safety of this drugs have been analyzed. The results of a recently published international trial DAPAHF studied the cardioprotective properties of dapagliflozin in HF, have been considered. The unique pleotropic cardiovascular properties of SGLT2 inhibitors (dapagliflozin) and their ability to prevent the progression of HF and reduce cardiovascular mortality allow us to hope that these drugs have a specific cardioprotective activity with respect to the treatment of HF with the reduced and preserved ejection fraction. Glyflosins, particularly dapagliflozine, are believed to be the fifth class of drugs recommended for the treatment of CH withthe reduced left volume ejection fraction, regardless of the presence or absence of DM2.Conclusions. It is expected that the results of the new studies will demonstrate the additional advantages of SGLT2 inhibitors in patients with and without cardiovascular diseases, CH with and without of DM2 and will help to better understand the mechanisms of their action, change approaches to the treatment of many patients.
Giugliano, D., & Esposito, K. (2019). Class effect for SGLT-2 inhibitors: a tale of 9 drugs. Cardiovascular Diabetology, 18(1). https://doi.org/10.1186/s12933-019-0899-9
Åkerblom, A., Oldgren, J., Latva-Rasku, A., Johansson, L., Lisovskaja, V., Karlsson, C., … Nuutila, P. (2019). Effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency, and myocardial contractile work in type 2 diabetes patients—a description of the DAPACARD study. Upsala Journal of Medical Sciences, 124(1), 59–64. https://doi.org/10.1080/03009734.2018.1515281
Patel, D. K., & Strong, J. (2019). The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit. Diabetes Therapy, 10(5), 1771–1792. https://doi.org/10.1007/s13300-019-00686-z
McMurray, J. J. V., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., … Sabatine, M. S. (2019). A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF). European Journal of Heart Failure, 21(5), 665–675. https://doi.org/10.1002/ejhf.1432
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., … Sabatine, M. S. (2019). Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 380(4), 347–357. https://doi.org/10.1056/nejmoa1812389
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., … Sabatine, M. S. (2018). The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial. American Heart Journal, 200, 83–89. https://doi.org/10.1016/j.ahj.2018.01.012
Olgar, Y., & Turan, B. (2019). A sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin comparison with insulin shows important effects on Zn2+-transporters in cardiomyocytes from insulin-resistant metabolic syndrome rats through inhibition of oxidative stress. Canadian Journal of Physiology and Pharmacology, 97(6), 528–535. https://doi.org/10.1139/cjpp-2018-0466
Mancini, S. J., Boyd, D., Katwan, O. J., Strembitska, A., Almabrouk, T. A., Kennedy, S., … Salt, I. P. (2018). Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms. Scientific Reports, 8(1). https://doi.org/10.1038/s41598-018-23420-4
Meng, L., Uzui, H., Guo, H., & Tada, H. (2018). Role of SGLT1 in high glucose level-induced MMP-2 expression in human cardiac fibroblasts. Molecular Medicine Reports, 17, 6887–6892. https://doi.org/10.3892/mmr.2018.8688
Basu, D., Huggins, L.-A., Scerbo, D., Obunike, J., Mullick, A. E., Rothenberg, P. L., … Goldberg, I. J. (2018). Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition. Arteriosclerosis, Thrombosis, and Vascular Biology, 38(9), 2207–2216. https://doi.org/10.1161/atvbaha.118.311339
Kondo, H., & Takahashi, N. (2019). Reduced hospitalization for heart failure using anti-diabetic drug dapagliflozin: implications of DECLARE–TIMI 58 for the basic science community. Cardiovascular Research, 115(6), e54–e57.. https://doi.org/10.1093/cvr/cvz073
Díaz-Rodríguez, E., Agra, R. M., Fernández, Á. L., Adrio, B., García-Caballero, T., González-Juanatey, J. R., & Eiras, S. (2017). Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability. Cardiovascular Research, 114(2), 336–346. https://doi.org/10.1093/cvr/cvx186
Sato, T., Aizawa, Y., Yuasa, S., Kishi, S., Fuse, K., Fujita, S., … Okabe, M. (2018). The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovascular Diabetology, 17(1). https://doi.org/10.1186/s12933-017-0658-8
Tang, H., Fang, Z., Wang, T., Cui, W., Zhai, S., & Song, Y. (2016). Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus. The American Journal of Cardiology, 118(11), 1774–1780. https://doi.org/10.1016/j.amjcard.2016.08.061
Monami, M., Dicembrini, I., & Mannucci, E. (2016). Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. Acta Diabetologica, 54(1), 19–36. https://doi.org/10.1007/s00592-016-0892-7
Saad, M., Mahmoud, A. N., Elgendy, I. Y., Abuzaid, A., Barakat, A. F., Elgendy, A. Y., … Mukherjee, D. (2017). Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials. International Journal of Cardiology, 228, 352–358. https://doi.org/10.1016/j.ijcard.2016.11.181
Sonesson, C., Johansson, P. A., Johnsson, E., & Gause-Nilsson, I. (2016). Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovascular Diabetology, 15(1). https://doi.org/10.1186/s12933-016-0356-y
Usman, M. S., Siddiqi, T. J., Memon, M. M., Khan, M. S., Rawasia, W. F., Talha Ayub, M., … Golzar, Y. (2018). Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis. European Journal of Preventive Cardiology, 25(5), 495–502. https://doi.org/10.1177/2047487318755531
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., … Langkilde, A.-M. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 381(21), 1995–2008. https://doi.org/10.1056/nejmoa1911303
Copyright (c) 2020 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).